Cantor Fitzgerald reiterated their overweight rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a research report released on Tuesday morning, Benzinga reports. The firm currently has a $85.00 price objective on the stock. Several other equities research analysts also recently commented on the company. Morgan Stanley reduced their target price on Disc […]
Cantor Fitzgerald reissued their overweight rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a report issued on Tuesday morning, Benzinga reports. They currently have a $85.00 target price on the stock. IRON has been the subject of a number of other reports. Wedbush reaffirmed an outperform rating and set a $43.00 price […]
Monoclonal Antibody Investigated for Anemia of CKD renalandurologynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from renalandurologynews.com Daily Mail and Mail on Sunday newspapers.
Disc Medicine (NASDAQ:IRON – Get Free Report)‘s stock had its “overweight” rating restated by stock analysts at Cantor Fitzgerald in a research report issued on Tuesday, Benzinga reports. They currently have a $85.00 price target on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 148.97% from the company’s current price. Several […]
Cantor Fitzgerald reiterated their overweight rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a research note released on Tuesday morning, Benzinga reports. They currently have a $85.00 price target on the stock. Several other research analysts have also weighed in on IRON. Stifel Nicolaus upped their price target on Disc Medicine from […]